



IMPROVING LAB SAFETY IN
ACADEMIA: FREE AND
INEXPENSIVE METHODS TO
IDENTIFY HIGH-RISK CHEMISTRY

JEFFREY B. SPERRY, PH.D.

MAY 2023

©2023 Vertex Pharmaceuticals Incorporated

OUTLINE

Introduction to Hazard and Risk **Defining Chemical Hazards** Inexpensive and Free Methods for Identifying Chemical Hazards Working at Vertex



Where we started













Where we are













Carelton University

Where we are







Yale University







Princeton University



Carelton University

The journey



Texas Tech (2010)

https://www.csb.gov/csb-releases-investigation-into-2010-texas-tech-laboratory-accident-case-study-identifies-systemic-deficiencies-in-university-safety-management-practices/









University of Hawaii (2016)

https://cen.acs.org/articles/94/web/2016/04/Spark-pressure-gauge-caused-University.html









10

PRESENTATION GOALS

A review and critique of academic lab safety research

A. Dana Ménard¹ and John F. Trant²

Over the past ten years, there have been several high-profile accidents in academic laboratories around the world, resulting in significant injuries and fatalities. The aftermath of these incidents is often characterized by calls for rection and re-examination of the academic discipline's approach to safety research and policy. However, the study of academic lab safety is still underdeveloped and necessary data about changes in safety attitudes and behaviours has not been gathered. This Review article critically examines the state of academic chemical safety research from a multiractorial stance for the accurrence of lab accidents, contributors to lab accidents, the state of safety training research and the cultural barriers to conducting safety research and implementing safer lab practices. The Review concludes by delineating research questions that must be addressed to minimize future serious academic laboratory incidents as well as stressing the need for committed leadership from our research institutions.



"In one survey from Nature and UCLA of 2,400 scientists, 30% reported having witnessed a lab injury severe enough to warrant attention from a medical professional"

A review and critique of academic lab safety research

A. Dana Ménard¹ and John F. Trant²

Over the past ten years, there have been several high-profile accidents in academic laboratories around the world, resulting in significant injuries and fatalities. The aftermath of these incidents is often characterized by calls for fection and re-examination of the academic discipline's approach to safety research and policy. However, the study of academic lab safety is still underdeveloped and necessary data about changes in safety attitudes and behaviours has not been gathered. This Review article critically examines the state of academic chemical safety research from a multifactorial stance, including research on the occurrence of lab accidents, contributors to lab accidents, the state of safety training research and the cultural barriers to conducting safety research and implementing safer lab practices. The Review concludes by delineating research questions that must be addressed to minimize future serious academic laboratory incidents as well as stressing the need for committed leadership from our research institutions.

11



"In one survey from Nature and UCLA of 2,400 scientists, 30% reported having witnessed a lab injury severe enough to warrant attention from a medical professional"

A review and critique of academic lab safety research

A. Dana Ménard 11 and John F. Trant 22

Over the past ten years, there have been several high-profile accidents in academic laboratories around the world, resulting in significant injuries and fatalities. The aftermath of these incidents is often characterized by calls for reflection and re-examination of the academic discipline's approach to safety research and policy. However, the study of academic lab safety is still underdeveloped and necessary data about changes in safety attitudes and behaviours has not been gathered. This Review article critically examines the state of academic chemical safety research from a multifactorial stance, including research on the occurrence of lab accidents, contributors to lab accidents, the state of safety training research and the cultural barriers to conducting safety research and implementing safer lab practices. The Review concludes by delineating research questions that must be addressed to minimize future serious academic laboratory incidents as well as stressing the need for committed leadership from our research institutions.

"In 2016, Grabowski and Goode found that only 8% of the 726 chemistry journals they identified required safety factors to be mentioned in the manuscript."



"In one survey from Nature and UCLA of 2,400 scientists, 30% reported having witnessed a lab injury severe enough to warrant attention from a medical professional"

A review and critique of academic lab safety research

A. Dana Ménard¹ and John F. Trant²

Over the past ten years, there have been several high-profile accidents in academic laboratories around the world, resulting in significant injuries and fatalities. The aftermath of these incidents is often characterized by calls for fection and re-examination of the academic discipline's approach to safety research and policy. However, the study of academic lab safety is still underdeveloped and necessary data about changes in safety attitudes and behaviours has not been gathered. This Review article critically examines the state of academic chemical safety research from a multifactorial stance, including research on the occurrence of lab accidents, contributors to lab accidents, the state of safety training research and the cultural barriers to conducting safety research and implementing safer lab practices. The Review concludes by delineating research questions that must be addressed to minimize future serious academic laboratory incidents as well as stressing the need for committed leadership from our research institutions.

"In 2016, Grabowski and Goode found that only 8% of the 726 chemistry journals they identified required safety factors to be mentioned in the manuscript."

"In Ayi and Hon's study, 27% of participants, active experimental researchers, stated that they never conducted any kind of risk assessment before performing laboratory work"



"In one survey from Nature and UCLA of 2,400 scientists, 30% reported having witnessed a lab injury severe enough to warrant attention from a medical professional"

A review and critique of academic lab safety research

A. Dana Ménard¹ and John F. Trant²

Over the past ten years, there have been several high-profile accidents in academic laboratories around the world, resulting in significant injuries and fatalities. The aftermath of these incidents is often characterized by calls for fection and re-examination of the academic discipline's approach to safety research and policy. However, the study of academic lab safety is still underdeveloped and necessary data about changes in safety attitudes and behaviours has not been gathered. This Review article critically examines the state of academic chemical safety research from a multifactorial stance, including research on the occurrence of lab accidents, contributors to lab accidents, the state of safety training research and the cultural barriers to conducting safety research and implementing safer lab practices. The Review concludes by delineating research questions that must be addressed to minimize future serious academic laboratory incidents as well as stressing the need for committed leadership from our research institutions.

"In 2016, Grabowski and Goode found that only 8% of the 726 chemistry journals they identified required safety factors to be mentioned in the manuscript."

"In Ayi and Hon's study, 27% of participants, active experimental researchers, stated that they never conducted any kind of risk assessment before performing laboratory work"

"...who found that only 40% of their participants and academic researchers reported wearing PPE at all times when working"

https://www.nature.com/articles/s41557-019-0375-x.pdf?origin=ppub





<u>Hazard</u>: A Hazard is a <u>potential</u>
source of harm or adverse
health effect on a person or
persons



17

© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com

<u>Hazard</u>: A Hazard is a <u>potential</u> <u>source of harm or adverse</u> <u>health effect</u> on a person or persons

Risk: Risk is the probability that a person may be harmed or suffers adverse health effects if exposed to a hazard x severity of the exposure



18

© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com



What is the hazard?



What is the hazard? Unsafe working at height



What is the hazard? Unsafe working at height

What is the **risk** that the person may be harmed?



Probable: 3 High - 9 High - 6 Medium - 3

Moderate: 2 Marginal: 1

Probable: 3 High - 9 High - 6 Medium - 3

Improbable: 1 Medium - 3 Low - 2 Low - 1

Probability



Severity



Risk

© 2023 Vertex Pharmaceuticals Incorporated

22





Probability



Severity



Risk

Improbable = 1

Moderate = 2

Low = 2

©2023 Vertex Pharmaceuticals Incorporated



What is the hazard?

Unsafe working at height





What is the hazard?

Unsafe working at height

What is the risk that the person may be harmed?





What is the hazard?

Unsafe working at height

What is the **risk** that the person may be harmed?




Low Risk

The hazard is the same, but the risk of injury is different!

High Risk

HOW DO WE REDUCE RISK OF EXPOSURE TO A HAZARD?





In 2016, OSHA implemented the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) in the U.S.

The GHS system, part of OSHA's Hazard Communication Standard (HCS), consists of nine symbols providing recognition of the hazards associated with certain substances. Use of eight of the nine are mandatory in the U.S., the exception being the environmental pictogram.





















Health Hazard

Carcinogen, mutagenicity, reproductive toxicity, respiratory sensitizer, target organ toxicity, aspiration toxicity



Exclamation Mark

Irritant (skin and eye), skin sensitizer, acute toxicity (harmful), narcotic effects, respiratory tract irritant, hazardous to ozone layer



Flame Over Circle

Oxidizers



Flame

Flammables, pyrophorics, self-heating, emits flammable gas, self-reactives, organic peroxides



Gas Cylinder

Gases under pressure



Skull and Crossbones

Acute toxicity (death)



Exploding Bomb Explosives, self-reactives,



Corrosion

Skin corrosion/burns, eye damage, corrosive to metals



Environmental

Environmental toxicity

©2023 Vertex Pharmaceuticals Incorporated

HAZARD AWARENESS CHART

HAZARD CLASSIFICATIONS





COLOUR BAR FORMAT

HAZARD INDEX

- 4 SEVERE HAZARD
- 3 SERIOUS HAZARD
- 2 MODERATE HAZARD
- 1 SLIGHT HAZARD
- 0 MINIMAL HAZARD

PERSONAL PROTECTION PICTOGRAMS —





















Safety







Mask











Explosive



Self-Contained Air Respirator



Boots







Acute Toxic



Hazard



Severe Toxic (not mandated



in U.S.)

Flame


Environmental

Biohazard Infectious


Materials





IDENTIFYING CHEMICAL HAZARDS - SWISS CHEESE MODEL





- Inexpensive (< \$1,000)
 - Bretherick's Handbook of Reactive Chemical Hazards
 - Sittig's Handbook of Toxic and Hazardous Chemicals and Carcinogens
 - Sax's Dangerous Properties of Industrial Materials
 - Wiley Guide to Chemical Incompatibilities
 - Comprehensive Guide to the Hazardous Properties of Chemical Substances












BRETHERICK'S HANDBOOK OF REACTIVE CHEMICAL HAZARDS


- The "Gold Standard" for reactive chemical hazards
- Covers unexpected loss of containment and explosion hazards from chemicals
- Also discloses incidents, some anecdotal
- Easily searchable, good reference list
- Cost: ~\$550; Also available online!



35


WILEY GUIDE TO CHEMICAL INCOMPATIBILITIES

- My #2 recommendation (Bretherick's is #1)
- Hard-to-find data on over 11,000 chemical substances
- Easy to search alphabetical organization and CAS numbers to avoid confusion
- Cost: ~\$800 (3rd Edition); ~\$200 (2nd Edition)



COMPREHENSIVE GUIDE TO THE HAZARDOUS PROPERTIES OF CHEMICAL **SUBSTANCES**

- Examines organics, metals and inorganics, industrial solvents, common gases, particulates, explosives, and radioactive substances, covers toxicity, carcinogenicity, flammability, explosive reactivity, handling, and disposal practices
- Arranges hazardous chemical substances according to their chemical structures and functional groups for easy reference
- Includes updated information on the toxic, flammable, and explosive properties of chemical substances
- metals
- Covers additional metals in the chapters on toxic and reactive




Cost: ~\$250

https://www.wilev.com/en-ie/A+Comprehensive+Guide+to+the+Hazardous+Properties+of+Chemical+Substances,+3rd+Edition-p-9780471714583


SITTIG'S HANDBOOK OF TOXIC AND HAZARDOUS CHEMICALS AND CARCINOGENS

- Covers 2,100 of the most heavily used, transported and regulated chemicals of both occupational and environmental concern
- Chemicals are presented alphabetically and classified as a carcinogen, hazardous substance, hazardous waste, or toxic pollutant
- Highly valuable to engineers and manufacturing personnel
- Cost: ~\$475



SAX'S DANGEROUS PROPERTIES OF INDUSTRIAL MATERIALS


- Three volume set first introduced in the 1950s
- Only reference that combines data on toxicological, fire, reactivity, explosive potential, and regulatory information
- Now in its twelfth edition, it contains extensive data on approximately 28,000 substances, including 2000 new entries
- Cost: ~\$750



https://www.wiley.com/en-us/Sax's+Dangerous+Properties+of+Industrial+Materials,+5+Volume+Set,+12th+Edition-p-9780470623251

IDENTIFYING CHEMICAL HAZARDS – FREE RESOURCES

IDENTIFYING CHEMICAL HAZARDS – FREE RESOURCES





$\frac{\text{Rule of Six}}{\underset{\text{No}_2}{\text{No}_2}} \xrightarrow{\underset{\text{No}_2}{\text{No}_2}} \xrightarrow{\underset{\text{No}_2}{\text{H}_2N-\overset{\circ}{\text{O}}}} \underset{\text{No}_2}{\underset{\text{No}_2}{\text{No}_2}} \xrightarrow{\underset{\text{No}_2}{\text{No}_2}} \xrightarrow{\underset{\text{N$

Oxygen Balance Calculation

Oxygen Balance =
$$\frac{\left[-1600\left(2X + \frac{Y}{2} - Z\right)\right]}{MW}$$

HEFG List

High Energy Functional Groups (HEFG) All Substances Containing:			
-	Acetylenic, metal acetylides, haloacetylene derivatives, allenes, etc.	X	X= C,O,N. Cyclopropanes, epoxides, and aziridines
Ĭ	X= O,N. Oxetanes and azetidines		X= C,N. 1,3,5-triazines and pyrimidines
>N—N < >N—N=	Hydrazines, hydrazones, etc	—n==n— —*n===n	N-N double or triple bonds, i.e. pyridizines, azo, diazonium salts, azides, diazirines and other high nitrogen containing compounds like triazoles, triazenes, tetrazoles, etc.
00-	O-O bonds, i.e. peroxides, peroxyacids and their salts, hydroperoxides, peroxyesters, etc.	—-м—-х	Halogen azides, N-halogen compounds, N- haloimides, etc.
—-о—-х	Alkyl perchlorates, aminium perchlorates, chlorite salts, halogen oxides, hypohalites, perchloryl compounds, etc. including bromates and iodates.	—_N==0 —_N==0	N-O bonds, such as isozazoles, nitro, nitroso, hydroxylamines, nitrite, nitrate, fulminates, oximes, oximates, etc.
—-м—-м	Metal nitrides, amides, hydrazides, imides, cyanamide. Main concern is the pyrophoric nature of the pure solid material. Dilute solutions of metal amides and substituted amides (i.e. LDA, LiHMDS) are generally acceptable depending on use and fate of excess quantities.	Ar————————————————————————————————————	Non-catalytic use of haloaryimetals, haloarenemetal pi-complexes. Note: Only Grignards of concern are halo- phenyl Grignards containing trifluoromethyl moleties.

ExFG List

Structural Feature	Examples
C – C Unsaturation	Acetylene, acetylides, 1,2-dienes (allenes)
C-Metal, N-Metal	Grignard reagents, organo-lithium species
Contiguous nitrogen atoms	Azides, aliphatic azo compounds, diazonium salts, hydrazines, sulfonyl hydrazides
Contiguous oxygen atoms	Peroxides, ozonides
N-O	Nitro, nitroso, nitrates, hydroxylamines, N-oxides,
N-halogen, O-halogen	Chloramines, fluoroamines, chlorates, perchlorates, iodosyl compounds

- The Hazard Communication Standard (HCS) (29 CFR 1910.1200(g)), revised in 2012, requires that the chemical manufacturer, distributor, or importer provide Safety Data Sheets (SDSs) for each hazardous chemical to downstream users to communicate information on these hazards.
- SDSs are required to be presented in a consistent user-friendly, 16-section format.



© 2023 Vertex Pharmaceuticals Incorporated

Section 1. Identification	Section 9. Physical and Chemical Properties
Section 2. Hazard(s) Identification	Section 10. Stability and Reactivity
Section 3. Composition/Information on Ingredients	Section 11. Toxicological Information
Section 4. First-Aid Measures	Section 12. Ecological Information (non-mandatory)
Section 5. Fire-Fighting Measures	Section 13. Disposal Considerations (non-mandatory)
Section 6. Accidental Release Measures	Section 14. Transport Information (non-mandatory)
Section 7. Handling and Storage	Section 15. Regulatory Information (non-mandatory)
Section 8. Exposure Controls/Personal Protection	Section 16. Other Information

Section 1. Identification	Section 9. Physical and Chemical Properties
Section 2. Hazard(s) Identification	Section 10. Stability and Reactivity
Section 3. Composition/Information on Ingredients	Section 11. Toxicological Information
Section 4. First-Aid Measures	Section 12. Ecological Information (non-mandatory)
Section 5. Fire-Fighting Measures	Section 13. Disposal Considerations (non-mandatory)
Section 6. Accidental Release Measures	Section 14. Transport Information (non-mandatory)
Section 7. Handling and Storage	Section 15. Regulatory Information (non-mandatory)
Section 8. Exposure Controls/Personal Protection	Section 16. Other Information

Section 1. Identification	Section 9. Physical and Chemical Properties
Section 2. Hazard(s) Identification	Section 10. Stability and Reactivity
Section 3. Composition/Information on Ingredients	Section 11. Toxicological Information
Section 4. First-Aid Measures	Section 12. Ecological Information (non-mandatory)
Section 5. Fire-Fighting Measures	Section 13. Disposal Considerations (non-mandatory)
Section 6. Accidental Release Measures	Section 14. Transport Information (non-mandatory)
Section 7. Handling and Storage	Section 15. Regulatory Information (non-mandatory)
Section 8. Exposure Controls/Personal Protection	Section 16. Other Information

SECTION 2. HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW

Powder

White to tan or light pink

Odor unknown

Toxic if swallowed.

Prolonged exposure may cause serious health effects.

May be irritating to skin and eyes.

Mutagen.

May cause cancer.

May cause allergic reactions in susceptible individuals.

Causes birth defects.

Causes impaired fertility.

Causes effects to:

gastrointestinal tract

blood

bone marrow

immune system

male reproductive system

fetus

May cause effects to:

eye

skin

liver

respiratory system

Harmful to aquatic organisms.

May cause long-term adverse effects in the aquatic environment.

Section 1. Identification	Section 9. Physical and Chemical Properties
Section 2. Hazard(s) Identification	Section 10. Stability and Reactivity
Section 3. Composition/Information on Ingredients	Section 11. Toxicological Information
Section 4. First-Aid Measures	Section 12. Ecological Information (non-mandatory)
Section 5. Fire-Fighting Measures	Section 13. Disposal Considerations (non-mandatory)
Section 6. Accidental Release Measures	Section 14. Transport Information (non-mandatory)
Section 7. Handling and Storage	Section 15. Regulatory Information (non-mandatory)
Section 8. Exposure Controls/Personal Protection	Section 16. Other Information

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

The following guidance applies to the handling of the active ingredient(s) in this formulation. The end-user should perform an appropriate risk assessment when handling other forms or formulations of this active ingredient.

OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 5: <1 mcg/m³. Materials in an OEB 5 category are considered extreme health hazards. The OEB is a range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

INTERNAL OCCUPATIONAL EXPOSURE LIMIT (8-hr TWA):

0.6 mcg/ m3

Wipe Limit:

6 mcg/100 cm2

Section 1. Identification	Section 9. Physical and Chemical Properties
Section 2. Hazard(s) Identification	Section 10. Stability and Reactivity
Section 3. Composition/Information on Ingredients	Section 11. Toxicological Information
Section 4. First-Aid Measures	Section 12. Ecological Information (non-mandatory)
Section 5. Fire-Fighting Measures	Section 13. Disposal Considerations (non-mandatory)
Section 6. Accidental Release Measures	Section 14. Transport Information (non-mandatory)
Section 7. Handling and Storage	Section 15. Regulatory Information (non-mandatory)
Section 8. Exposure Controls/Personal Protection	Section 16. Other Information

SECTION 10. STABILITY AND REACTIVITY

STABILITY/ REACTIVITY:

Stable under normal conditions.

INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID:

Heat. Oxidizers. Strong acids and bases.

HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:

Carbon oxides (COx). Nitrogen oxides (NOx).



pubs.acs.org/OPRD Perspective

When Safety Data Sheets are a Safety Hazard

Alexander G. Kolchinski*



ABSTRACT: Over the past several decades, Material Safety Data Sheets (MSDSs) and, more recently, Safety Data Sheets (SDSs) have become a valuable source of safety information for both industry and academia. They provide chemists with important data on reactivity, toxicity, decomposition byproducts, etc., thus preventing various chemical accidents. Conversely, when the SDS contains erroneous information, serious accidents can ensue. This article provides examples of erroneous statements found in SDSs and analyzes their origins. Several measures are also proposed to improve the quality of SDSs.

KEYWORDS: safety data sheets, safety in chemistry laboratory, chemistry accidents, erroneous statements in SDSs

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00427

© 2023 Vertex Pharmaceuticals Incorporated

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

The following guidance applies to the handling of the active ingredient(s) in this formulation. The end-user should perform an appropriate risk assessment when handling other forms or formulations of this active ingredient.

OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 5: <1 mcg/m³. Materials in an OEB 5 category are considered extreme health hazards. The OEB is a range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

Temozolomide (TMZ)

INTERNAL OCCUPATIONAL EXPOSURE LIMIT (8-hr TWA):

0.6 mcg/ m3 for

Wipe Limit:

6 mcg/100 cm2

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

The following guidance applies to the handling of the active ingredient(s) in this formulation. The end-user should perform an appropriate risk assessment when handling other forms or formulations of this active ingredient.

OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 5: <1 mcg/m³. Materials in an OEB 5 category are considered extreme health hazards. The OEB is a range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

Temozolomide (TMZ)

INTERNAL OCCUPATIONAL EXPOSURE LIMIT (8-hr TWA):

0.6 mcg/ m3 for

Wipe Limit:

6 mcg/100 cm2

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

This product contains no substances with occupational exposure limit values.

8.2 Exposure controls

Engineering controls

Ensure adequate ventilation. Provide accessible safety shower and eye wash station.

Personal protective equipment

Eye protection Safety goggles with side-shields.

Hand protection Protective gloves.

Skin and body protection Impervious clothing.

Respiratory protection Suitable respirator.

Environmental exposure controls Keep the product away from drains, water courses or the soil.

Clean spillages in a safe way as soon as possible.

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

The following guidance applies to the handling of the active ingredient(s) in this formulation. The end-user should perform an appropriate risk assessment when handling other forms or formulations of this active ingredient.

OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 5: <1 mcg/m³. Materials in an OEB 5 category are considered extreme health hazards. The OEB is a range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

Temozolomide (TMZ)

INTERNAL OCCUPATIONAL EXPOSURE LIMIT (8-hr TWA):

0.6 mcg/ m3 for

Wipe Limit:

6 mcg/100 cm2

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

This product contains no substances with occupational exposure limit values.

8.2 Exposure controls

Engineering controls

Ensure adequate ventilation. Provide accessible safety shower and eye wash station.

Personal protective equipment

Eye protection Safety goggles with side-shields.

Hand protection Protective gloves.

Skin and body protection Impervious clothing.

Respiratory protection Suitable respirator.

Environmental exposure controls Keep the product away from drains, water courses or the soil.

Clean spillages in a safe way as soon as possible.

Temozolomide (TMZ)

IDENTIFYING CHEMICAL HAZARDS – HEFG LIST

IDENTIFYING CHEMICAL HAZARDS – HEFG LIST

- A high-energy functional group (HEFG) is any functional group that is known to contribute to the exothermic decomposition of a molecule
- Compounds containing one or more HEFGs may be unsafe at any temperature
- The more HEFGs a compound has, the more exothermic its decomposition and the less stable

IDENTIFYING CHEMICAL HAZARDS – HEFG LIST

High Energy Functional Groups (HEFG)

- A high-energy functional group (HEFG) is any functional group that is known to contribute to the exothermic decomposition of a molecule
- Compounds containing one or more HEFGs may be unsafe at any temperature
- The more HEFGs a compound has, the more exothermic its decomposition and the less stable

All Substances Containing:

<u> </u>	Acetylenic, metal acetylides, haloacetylene derivatives, allenes, etc.	X	X= C,O,N. Cyclopropanes, epoxides, and aziridines
X	X= O,N. Oxetanes and azetidines	×	X= C,N. 1,3,5-triazines and pyrimidines
N—N N—N=	Hydrazines, hydrazones, etc	—_N==_N— *N===N	N-N double or triple bonds, i.e. pyridizines, azo, diazonium salts, azides, diazirines and other high nitrogen containing compounds like triazoles, triazenes, tetrazoles, etc.
oo	O-O bonds, i.e. peroxides, peroxyacids and their salts, hydroperoxides, peroxyesters, etc.	x	Halogen azides, N-halogen compounds, N-haloimides, etc.
—-ох	Alkyl perchlorates, aminium perchlorates, chlorite salts, halogen oxides, hypohalites, perchloryl compounds, etc. including bromates and iodates.	—N0 —_N0	N-O bonds, such as isozazoles, nitro, nitroso, hydroxylamines, nitrite, nitrate, fulminates, oximes, oximates, etc.
—м	Metal nitrides, amides, hydrazides, imides, cyanamide. Main concern is the pyrophoric nature of the pure solid material. Dilute solutions of metal amides and substituted amides (i.e. LDA, LiHMDS) are generally acceptable depending on use and fate of excess quantities.	Ar——M——X X——Ar——M	Non-catalytic use of haloarylmetals, haloarenemetal pi-complexes. Note: Only Grignards of concern are halophenyl Gringnards containing trifluoromethyl moieties.

57

© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com

IDENTIFYING CHEMICAL HAZARDS – EXFG LIST

- An explosive functional group (ExFG) is a functional group that can give a molecule explosive properties
- Every ExFG is also an HEFG but not all HEFGs are ExFGs
- The more ExFGs a compound has, the more likely it is to be classified as an explosive material

IDENTIFYING CHEMICAL HAZARDS – EXFG LIST

- An explosive functional group (ExFG) is a functional group that can give a molecule explosive properties
- Every ExFG is also an HEFG but not all HEFGs are ExFGs
- The more ExFGs a compound has, the more likely it is to be classified as an explosive material

Structural Feature	Examples
C – C Unsaturation	Acetylene, acetylides, 1,2-dienes (allenes)
C-Metal, N-Metal	Grignard reagents, organo-lithium species
	Azides, aliphatic azo compounds, diazonium salts,
Contiguous nitrogen atoms	hydrazines, sulfonyl hydrazides
Contiguous oxygen atoms	Peroxides, ozonides
	Nitro, nitroso, nitrates, hydroxylamines, N-oxides,
N-O	1,2-oxazoles
	Chloramines, fluoroamines, chlorates,
N-halogen, O-halogen	perchlorates, iodosyl compounds

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.0c00467

Rule of 6

- Introduced by Peer in 1998
- Originally applied to azides but has since been applied to other materials containing explosive functional groups
- The "Rule of Six" states: If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Peer, M. Spec. Chem. 1998, 18, 256 - 263.

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?



Rule of Six:

Explosive?

Safe to Handle?

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?



Rule of Six: Pass

Explosive? No

Safe to Handle? Yes

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

$$O_2N$$
 NO_2
 NO_2

Rule of Six: Pass

Explosive? No

Safe to Handle? Yes

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

$$O_2N$$
 NO_2
 NO_2

Rule of Six: Pass Fail

Explosive? No Yes

Safe to Handle? Yes No

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

$$O_2N$$
 NO_2
 NO_2

Rule of Six:

Pass

Fail

Explosive?

No

Yes

Safe to Handle?

Yes

No

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

$$O_2N$$
 NO_2
 NO_2
 NO_2
 NO_2
 NO_2
 NO_2

Rule of Six: Pass Fail Pass

Explosive? No Yes Yes

Safe to Handle? Yes No Yes

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

$$O_2N$$
 NO_2

Rule of Six:

Pass

Fail

Pass

Explosive?

No

Yes

Yes

Safe to Handle?

Yes

No

Yes

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

Rule of Six:

Explosive?

Safe to Handle?

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

©2023 Vertex Pharmaceuticals Incorporate

IDENTIFYING CHEMICAL HAZARDS – RULE OF SIX

If a substance presents at least six atoms of carbon (or other atoms of approximately the same size) per energetic functionality (ExFG), this should render the molecule relatively safe to handle

Rule of Six Pass or Fail?

$$O_2N$$
 NO_2

Rule of Six:

Pass

Fail

Pass

Depends 1 ExFG = Pass; 2 ExFG = Fail

Explosive?

No

Yes

Yes

Yes

Safe to Handle?

Yes

No

Yes

No

Oxygen Balance: For an organic compound with a molecular formula of $C_XH_YO_Z$ and molecular weight (MW), the OB can be obtained by the following equation:

Oxygen Balance: For an organic compound with a molecular formula of $C_XH_YO_Z$ and molecular weight (MW), the OB can be obtained by the following equation:

$$Oxygen\ Balance = \frac{\left[-1600\left(2X + \frac{Y}{2} - Z\right)\right]}{MW}$$

Oxygen Balance: For an organic compound with a molecular formula of $C_XH_YO_Z$ and molecular weight (MW), the OB can be obtained by the following equation:

Oxygen Balance =
$$\frac{\left[-1600\left(2X + \frac{Y}{2} - Z\right)\right]}{MW}$$



Shanley, E. S.; Melhem, G. A. Process Saf. Prog. 1995, 14, 29 – 31

Compound	Oxygen Balance	Oxygen Balance Hazard Rank	Observed Hazard Rank
Hydrogen Peroxide	47	High	Medium-High
Water	0	High	None
Oxalic Acid	-18	High	None
Hydrazoic acid	-19	High	High
Acetyl peroxide	-95	High	High
Diazomethane	-114	High	High
t-Butyl Peroxide	-252	Low	High
Ethylene	-286	Low	Medium
Acetylene	-308	Low	High

Insoluble in DCM

CAMEO Chemicals

Home

Help

Search Chemicals

New Search

MyChemicals

chemicals: 0 View MyChemicals

Predict Reactivity

Mobile Site





Database of Hazardous Materials



Search

Find response information for thousands of hazardous materials, including fire and explosion hazards, health hazards, firefighting techniques, cleanup procedures, protective clothing, and chemical properties.



MyChemicals

Build a list of chemicals. For example, substances involved in an incident response (such as a train derailment) or chemicals stored in your community.



Reactivity

See what hazards might occur if chemicals in your MyChemicals collection are mixed together.

Get started by finding a substance of interest with a search.

Learn more by checking the help for background information, a glossary of terms, and guidance on using this database.

About | Privacy Policy | Contact Us | Website Satisfaction Survey | Mobile Site

https://cameochemicals.noaa.gov/

CAMEO Chemicals

Home

Help

Search Chemicals

New Search

MyChemicals

chemicals: 0 View MyChemicals

Predict Reactivity

Mobile Site





Database of Hazardous Materials



Search

Find response information for thousands of hazardous materials, including fire and explosion hazards, health hazards, firefighting techniques, cleanup procedures, protective clothing, and chemical properties.



MyChemicals

Build a list of chemicals. For example, substances involved in an incident response (such as a train derailment) or chemicals stored in your community.



Reactivity


See what hazards might occur if chemicals in your MyChemicals collection are mixed together.


Get started by finding a substance of interest with a search.

Learn more by checking the help for background information, a glossary of terms, and guidance on using this database.

About | Privacy Policy | Contact Us | Website Satisfaction Survey | Mobile Site

https://cameochemicals.noaa.gov/






© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com



© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




© 2023 Vertex Pharmaceuticals Incorporated globa




© 2023 Vertex Pharmaceuticals Incorporated




©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com




© 2023 Vertex Pharmaceuticals Incorporated







©2023 Vertex Pharmaceuticals Incorporated




Highly reactive - never mix bromine and THF



SWISS CHEESE MODEL



Laboratory Incident



© 2023 Vertex Pharmaceuticals Incorporated



1. All scientists should be able to identify the 9 GHS chemical hazard symbols






















- 1. All scientists should be able to identify the 9 GHS chemical hazard symbols
- 2. All scientists should be able to perform basic risk assessments and identify high risk chemistry





© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com


- 1. All scientists should be able to identify the 9 GHS chemical hazard symbols
- 2. All scientists should be able to perform basic risk assessments and identify high risk chemistry
- 3. Five of my favorite references for identifying chemical hazards were discussed













- 1. All scientists should be able to identify the 9 GHS chemical hazard symbols
- 2. All scientists should be able to perform basic risk assessments and identify high risk chemistry
- 3. Five of my favorite references for identifying chemical hazards were discussed
- 4. Six free methodologies for identifying chemical hazards were also presented



© 2023 Vertex Pharmaceuticals Incorporated global.vrtx.com

- 1. All scientists should be able to identify the 9 GHS chemical hazard symbols
- 2. All scientists should be able to perform basic risk assessments and identify high risk chemistry
- 3. Five of my favorite references for identifying chemical hazards were discussed
- 4. Six free methodologies for identifying chemical hazards were also presented
- 5. The Hierarchy of Controls can be utilized to reduce risk of exposure to a hazard



TAKEAWAYS

- 1. All scientists should be able to identify the 9 GHS chemical hazard symbols
- 2. All scientists should be able to perform basic risk assessments and identify high risk chemistry
- 3. Five of my favorite references for identifying chemical hazards were discussed
- 4. Six free methodologies for identifying chemical hazards were also presented
- 5. The Hierarchy of Controls can be utilized to reduce risk of exposure to a hazard

My final words:

YOU are responsible for understanding the hazards of the chemicals you are working with.

Just because it is commercially available or labeled as a "safe alternative to..." does not mean that using the material is free from risk.




WE ARE VERTEX

We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets.



Patients are at the heart of everything we do



We strike at the core of serious diseases to change people's lives



We're not afraid to take on the impossible

For the lives we have changed and for those who are still waiting, we will never stop fighting until we discover cures.

QUICK FACTS



Founded:

1989



Headquarters:

Boston



~4,500

Employees worldwide (~3,500 in the U.S.)



\$58B

\$7.6B

Market Cap (as of Jan. 2022)

2021

Revenue



LEADING THE WAY

Our leadership team collectively brings decades of experience to our mission



Reshma Kewalramani, M.D. Chief Executive Officer and President



Jeffrey Leiden, M.D., Ph.D. Executive Chairman



David Altshuler, M.D., Ph.D. Executive VP, Global Research and Chief Scientific Officer



Stuart A. ArbuckleExecutive VP and Chief Operating
Officer



Jonathan BillerExecutive VP and Chief Legal
Officer



Carmen Bozic, M.D.Executive VP, Global Medicines
Development and Medical Affairs, and Chief Medical Officer



Amit K. SachdevExecutive VP and Chief Patient
Officer



Nia Tatsis, Ph.D.Executive VP and Chief Regulatory and Quality Officer



Bastiano Sanna, Ph.D.Executive VP, Chief of Cell and Genetic Therapies and VCGT
Site Head



Charles F. Wagner
Executive VP and Chief Financial
Officer

©2022 Vertex Pharmaceuticals Incorporated

OUR STRATEGY AND BUSINESS MODEL

A blueprint for serial innovation


CORPORATE STRATEGY

Vertex invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets

RESEARCH AND DEVELOPMENT STRATEGY

Combine transformative advances in the understanding of human disease and in the science of therapeutics to dramatically advance human health

- Focus on validated targets that address causal human biology
- Create predictive lab assays and clinical biomarkers
- Identify rapid path to registration and approval
- Discover and develop medicines that offer transformative benefit, regardless of modality



©2022 Vertex Pharmaceuticals Incorporated



PUTTING SCIENCE FIRST

We believe in the promise and potential of science to have a transformative impact for people living with serious diseases.





>70% of our operating expenses are dedicated to R&D, well above the average of the top pharma and biotech companies in the industry*



3 out of 5 Vertex employees are dedicated to R&D



Vertex is one of only a handful of companies to have internally discovered and developed five or more innovative medicines.**

^{*2021} GAAP figures. Operating expenses defined as R&D + Sales, General & Administrative.

^{**}Among biotech companies founded since 1976 as of December 2021

OUR STRATEGY IN ACTION

No matter the disease, our work is defined by a common strategy that drives a culture of innovation and scientific discovery.



Pioneers in CF research and development

We discovered, developed and produced the first medicines to target the underlying cause of cystic fibrosis.

Complementing our small molecule expertise with a toolkit in cell and genetic therapies

Vertex Cell and Genetic Therapies brings together our industry leading portfolio of technologies, teams and manufacturing capabilities.



When we decide to work on a disease, we investigate it from every angle.



OUR JOURNEY IN CYSTIC FIBROSIS

Cystic fibrosis (CF) is a rare, chronic, genetic disease that affects multiple organs, including the lungs, liver, gastrointestinal tract, pancreas, sinuses, sweat glands and reproductive tract.



Our track record in CF serial innovation

- 20+ years of R&D
- 4 approved medicines with the potential to treat up to ~90% of all people with CF
- ~20 ongoing clinical trials

Our commitment to finding treatments for all people with CF

- 1. Expanding access to our existing medicines
- 2. Discovering and testing additional combination therapies
- 3. Investigating genetic therapy approaches, like mRNA

ADVANCING OUR RESEARCH PROGRAMS IN SICKLE CELL DISEASE AND BETA THALASSEMIA

"It's not just the hospitalizations or the crises, but **just the daily aspects of living** with sickle cell disease that can be extremely challenging if you don't balance it very well."

 39-year-old mother, wife and advocate living with sickle cell disease



Sickle cell disease

Sickle cell disease causes severe pain, organ damage and a shortened life span due to misshapen or "sickled" blood cells.

Our approach:

- · Gene editing
- Small molecules

Beta thalassemia

Beta thalassemia primarily presents as anemia, or a lack of red blood cells. This can lead to many different complications and medical problems.

Our approach:

- Gene editing
- Small molecules

PIONEERING A POTENTIAL CELL THERAPY FOR TYPE 1 DIABETES

"Living with type 1 takes all of one's mental capacity and energy; it's difficult to focus on anything else..."

Adult living with type 1 diabetes



Type 1 diabetes

Type 1 diabetes is a metabolic, autoimmune disease where the cells in the pancreas (beta cells) that produce insulin are destroyed. Without proper management, it can lead to kidney disease, eye disease, nerve damage and even death.

Our approach:

- Cell therapy with immunosuppression
- Encapsulated islet cell therapy
- Cells that can evade (or hide from) the immune system

DISCOVERING POTENTIAL THERAPIES FOR APOL1-MEDIATED KIDNEY DISEASE

"For me, in my particular disease, it happened so rapidly — I felt like we were always more than one step behind in the treatment process."

45-year-old living with APOL1-mediated focal segmental glomerulosclerosis



APOL1-mediated kidney disease

APOL1-mediated kidney disease is a kidney disease associated with certain *APOL1* genetic mutations that can have various clinical presentations, including focal segmental glomerulosclerosis and other severe kidney disease. These diseases are more aggressive when associated with *APOL1* mutations and can lead to rapidly progressive kidney damage and potentially kidney failure.

Our approach: Small molecules

PURSUING INNOVATIVE THERAPIES FOR PAIN

"Pain is the determining factor that decides what I can accomplish during any given day. If my pain level is 10, there is no way to possibly concentrate on tasks at hand or socialize with family."

– 60-year-old living with pain



Pain

Pain is a potentially debilitating condition that develops from a variety of circumstances; it can be acute or chronic and range in severity.

Poorly managed pain can lead to a significant decrease in quality of life and is often associated with complications such as sleep interruption, immobility, inability to work and major depression.

Our approach: Small molecules

R&D PIPELINE AS OF OCTOBER 1, 2022


Cystic Fibrosis	VX-121/tezacaftor/VX-561 (Small Molecule)	Phase 1 Phase 2 Phase 3 Phase 4
	Additional Small Molecules	Research
	CRISPR/Cas9	Research
	mRNA Therapeutics	Research
Sickle Cell Disease	Exa-cel (CRISPR/Cas9)	Phase 1/2/3 Phase 4
	Small Molecule	Research
Beta Thalassemia	Exa-cel (CRISPR/Cas9)	Phase 1/2/3 Phase 4
	Small Molecule	Research
Pain	VX-548 (Small Molecule)	Phase 3 Phase 4
	Additional Small Molecules	Research
APOL1-Mediated Kidney Disease	Inaxaplin (Small Molecule)	Phase 2/3 Phase 4
	Additional Small Molecules	Research
Type 1 Diabetes	VX-880 (Cell Therapy)	Phase 1/2
	Encapsulated Islet Cells	Research
Alpha-1 Antitrypsin Deficiency	Small Molecules	Research
Duchenne Muscular Dystrophy	CRISPR/Cas9	Research

There is no guarantee that the investigational compounds listed will be approved by a Health Authority or will be marketed. Safety and effectiveness of investigational medicines have not been established.

123


© 2022 Vertex Pharmaceuticals Incorporated global.vrtx.com

COLLABORATIONS EXPAND OUR DRUG DISCOVERY TOOLBOX



Targets and Human Cell Models

- Q-State Biosciences
- Genomics plc



Innovation in Small Molecule Therapeutics

- Kymera Therapeutics
- Ribometrix
- Skyhawk Therapeutics
- X-Chem



Genetic Therapies

- Affinia Therapeutics
- Arbor Biotechnologies
- CRISPR Therapeutics
- Mammoth Biosciences
- Moderna
- Obsidian Therapeutics
- Verve Therapeutics



OUR DEEP COMMITMENT TO CORPORATE RESPONSIBILITY AND **ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)**

As a leading global biotech company, we're committed to operating our business responsibly. We focus our efforts on four corporate responsibility priorities.

Improve the lives of people with serious diseases

\$3B R&D investment in 2021

Make a positive impact in the communities where we are based

~2000 nonprofit organizations supported through the Vertex Foundation Matching Gift Program for employees

Foster an ethical culture that embraces innovation, inclusion, diversity & equity

>10 Best Places to Work,
Culture and ID&E awards

Carefully manage our operations and environmental footprint

20% goal to reduce carbon emissions reduction globally by end of 2023

score on CDP Climate Change Survey

Newsweek

COMPANIES 2022





2022 People' COMPANIES THAT CARE

©2022 Vertex Pharmaceuticals Incorporated

POSITIVELY IMPACTING OUR COMMUNITIES

The Vertex Foundation is a key part of our corporate giving commitment.

The Foundation seeks to improve the lives of people with serious diseases and contribute to the communities where Vertex is located through education, innovation and health.













INVESTING IN THE NEXT GENERATION OF SCIENTISTS

Boston VERTEX San Diego

- Summer internship program
- Afterschool program
- Vertex Science Leaders scholarship
- Summer internship program
- Afterschool program
- Vertex Science Leaders scholarship (launching in 2022)

Oxford, U.K.



- Summer internship program
- Weekly engagements with UTC Oxfordshire

In 2021:



20,000+

hours spent by students in Learning Lab programming



960+

hours volunteered by Vertex employees



10th

anniversary of paid internship program in Boston



10

interns completed a biotech curriculum with Year Up



THE VERTEX CULTURE

Different for a reason



We believe we can use **science** and **innovation** to do the impossible. We are **relentless** and **intense** in our approach, which is driven by our **strong sense of urgency** to bring transformative medicines to **patients** as quickly as we can. We are **inclusive**, roll up our sleeves and believe that good ideas come from everyone - we **debate vigorously**, hold each other **accountable** and **celebrate** our successes and **learn** from our failures to drive results.

OUR VALUES

"Our values and our culture have been a key driver of our success, and they're the reason our work environment is so productive, collaborative, inclusive and rewarding. It makes me proud to be a Vertexian."



Reshma Kewalramani, M.D., Chief Executive Officer and President she/her/hers









131

©2022 Vertex Pharmaceuticals Incorporated global.vrtx.com

OUR INCLUSION, DIVERSITY AND EQUITY (ID&E) PRIORITIES

Inclusion:

Equip all Vertexians with the skills and resources to activate and live ID&E in their day-to-day interactions and decisions

Diversity:

Invest to address gaps in representation in our talent pipeline, with a focus on racial, ethnic, cultural and gender equity

Equity:

Embed inclusive and equitable practices throughout the employee experience



- Delivered research-backed ID&E curriculum to enable all Vertexians to <u>Learn</u>, <u>Implement</u>, <u>Validate and <u>Embed</u> (LIVE) ID&E into their ways of working
 </u>
- Expanded career opportunities in biotech to talent from historically underrepresented populations by launching a first-of-its-kind biotechnology workforce development program with Boston-based Year Up
- Through 4 global employee-led resource networks, amplified the voices of Vertexians
- Furthered inclusive practices by enabling Vertexians to share their pronouns across multiple platforms

WE'RE CONSISTENTLY RECOGNIZED AS A TOP PLACE TO WORK



















LEARN MORE ABOUT VERTEX AND THE COMMUNITIES WE SERVE

Visit www.vrtx.com and follow us on our social media channels for the latest news and stories about our people and programs.

Our Social channels:

Facebook Page: <u>@VertexPharmaInc</u>

Instagram Page: @vertexpharmaceuticals

LinkedIn Page: <u>@Vertex Pharmaceuticals</u>

Twitter Page: <u>@VertexPharma</u> and <u>@VertexScience</u>

YouTube Page: <u>Vertex Pharmaceuticals</u>

For the lives we have changed and for those who are still waiting, we will never stop fighting until we discover cures.